The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV

This prespecified exploratory analyses from VERTIS CV (NCT01986881) aimed to assess the effects of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor ertugliflozin on glucosuria‐related (glycated haemoglobin [HbA1c], uric acid, body weight) and natriuresis‐related (blood pressure, haemoglobin, haematocrit, serum albumin) biomarkers according to kidney function risk category.

[1]  B. Perkins,et al.  Developmental Origins of Health and Disease Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus , 2014 .

[2]  M. Cooper,et al.  Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. , 2018, Kidney international.

[3]  W. Aronow.  Faculty Opinions recommendation of Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[4]  Dongli Tian,et al.  Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials , 2018, Diabetes, obesity & metabolism.

[5]  C. Cannon,et al.  Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial , 2021, Diabetologia.

[6]  D. V. van Raalte,et al.  Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials. , 2018, Kidney international.

[7]  C. Cannon,et al.  Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS‐CV) , 2018, American heart journal.

[8]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[9]  M. Busslinger,et al.  SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. , 2019, American journal of physiology. Renal physiology.

[10]  R. Aronson,et al.  Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[11]  S. Verma,et al.  Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. , 2020, Annual review of physiology.

[12]  K. Mahaffey,et al.  Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function , 2018, Circulation.

[13]  B. Zinman,et al.  Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. , 2020, Kidney international.

[14]  M. Kanbay,et al.  Renal physiology of glucose handling and therapeutic implications , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  Merlin C Thomas,et al.  The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure , 2018, Diabetologia.

[16]  H. Heerspink,et al.  Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[17]  C. Cannon,et al.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.

[18]  T. Nakanishi,et al.  SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria , 2014, Biopharmaceutics & drug disposition.

[19]  C. Cannon,et al.  Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes , 2020, JAMA cardiology.

[20]  V. Sahasrabudhe,et al.  The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus , 2017, Journal of clinical pharmacology.

[21]  H. Nagasu,et al.  Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice using In Vivo Imaging. , 2019, Circulation.

[22]  P. Lawler,et al.  Changes in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes , 2021, Diabetes Care.

[23]  D. Fitchett,et al.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.

[24]  C. Cannon,et al.  Gradient of Risk and Associations with Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations from VERTIS CV. , 2020, Circulation.

[25]  Chapter 1: Definition and classification of CKD , 2012, Kidney International Supplements.

[26]  C. Cannon,et al.  Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials , 2021, Clinical cardiology.

[27]  R. Zietse,et al.  Salt-Sensitive Hypertension in Chronic Kidney Disease: Distal Tubular Mechanisms. , 2020, American journal of physiology. Renal physiology.

[28]  V. Vallon,et al.  Renal Effects of Sodium-Glucose Co-Transporter Inhibitors. , 2019, The American journal of cardiology.